QuidelOrtho Croissance future

Future contrôle des critères 0/6

QuidelOrtho devrait augmenter ses bénéfices et son chiffre d'affaires de 98.5% et de 1.4% par an respectivement. Le BPA devrait croître de de 98.6% par an. Le rendement des capitaux propres devrait être 6.2% dans 3 ans.

Informations clés

98.5%

Taux de croissance des bénéfices

98.6%

Taux de croissance du BPA

Medical Equipment croissance des bénéfices	17.1%
Taux de croissance des recettes	1.4%
Rendement futur des capitaux propres	6.2%
Couverture par les analystes	Good
Dernière mise à jour	11 Nov 2024

Mises à jour récentes de la croissance future

Recent updates

Lacklustre Performance Is Driving QuidelOrtho Corporation's (NASDAQ:QDEL) Low P/S

Nov 17

QuidelOrtho (NASDAQ:QDEL) Seems To Be Using A Lot Of Debt

Sep 15

QuidelOrtho Corporation (NASDAQ:QDEL) Stock Catapults 38% Though Its Price And Business Still Lag The Industry

Aug 09

QuidelOrtho: Attractive Valuation Despite Weak Performance

Apr 13

We Think QuidelOrtho (NASDAQ:QDEL) Is Taking Some Risk With Its Debt

Apr 08

QuidelOrtho Corporation's (NASDAQ:QDEL) 38% Dip In Price Shows Sentiment Is Matching Revenues

Feb 15

QuidelOrtho Corporation (NASDAQ:QDEL) Shares Could Be 38% Below Their Intrinsic Value Estimate

Mar 13

QuidelOrtho Corporation Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Feb 18

An Intrinsic Calculation For QuidelOrtho Corporation (NASDAQ:QDEL) Suggests It's 47% Undervalued

Nov 25

QuidelOrtho forecasts strong Q3 revenue above estimates, shares rise ~6% after hours

Oct 12

QuidelOrtho: Fundamentals Remain, Upbeat Financials

Sep 14

Improved Earnings Required Before QuidelOrtho Corporation (NASDAQ:QDEL) Shares Find Their Feet

Sep 03

QuidelOrtho announces $300M share repurchase authorization

Aug 17

Robust Earnings May Not Tell The Whole Story For QuidelOrtho (NASDAQ:QDEL)

Aug 13

Quidel Non-GAAP EPS of $2.34 misses by $0.51, revenue of $613.4M misses by $27.21M

Aug 04

QuidelOrtho: Continuing Its Upward Ascent

Jul 08

Prévisions de croissance des bénéfices et des revenus

NasdaqGS:QDEL - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	2,899	-2	427	472	6
12/31/2025	2,776	-98	423	426	7
12/31/2024	2,763	-1,896	14	124	7
9/29/2024	2,818	-1,867	-97	100	N/A
6/30/2024	2,835	-1,859	-170	23	N/A
3/31/2024	2,863	-1,765	-119	91	N/A
12/31/2023	2,998	-10	71	280	N/A
10/1/2023	3,122	13	147	369	N/A
7/2/2023	3,162	45	109	318	N/A
4/2/2023	3,110	118	389	573	N/A
1/1/2023	3,266	549	744	885	N/A
10/2/2022	3,036	810	926	1,037	N/A
7/3/2022	2,762	1,006	936	1,124	N/A
4/3/2022	2,326	1,006	484	721	N/A
1/2/2022	1,699	704	513	806	N/A
10/3/2021	1,871	883	634	924	N/A
7/4/2021	1,837	900	712	917	N/A
3/31/2021	1,862	948	1,017	1,154	N/A
1/3/2021	1,662	810	565	630	N/A
9/30/2020	1,005	371	194	238	N/A
6/30/2020	655	155	152	181	N/A
3/31/2020	562	88	135	163	N/A
12/31/2019	535	73	107	134	N/A
9/30/2019	515	75	102	130	N/A
6/30/2019	506	69	117	147	N/A
3/31/2019	501	65	102	133	N/A
12/31/2018	522	74	105	136	N/A
9/30/2018	505	37	77	104	N/A
6/30/2018	438	20	N/A	67	N/A
3/31/2018	373	12	N/A	34	N/A
12/31/2017	278	-8	N/A	28	N/A
9/30/2017	216	-5	N/A	33	N/A
6/30/2017	214	0	N/A	38	N/A
3/31/2017	215	4	N/A	49	N/A
12/31/2016	192	-14	N/A	12	N/A
9/30/2016	189	-12	N/A	11	N/A
6/30/2016	187	-12	N/A	11	N/A
3/31/2016	183	-14	N/A	-3	N/A
12/31/2015	194	-6	N/A	37	N/A
9/30/2015	206	1	N/A	38	N/A
6/30/2015	201	-4	N/A	42	N/A
3/31/2015	197	-2	N/A	45	N/A
12/31/2014	184	-7	N/A	36	N/A
9/30/2014	169	-13	N/A	19	N/A
6/30/2014	160	-12	N/A	14	N/A
3/31/2014	158	-6	N/A	13	N/A
12/31/2013	177	7	N/A	26	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: QDEL devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: QDEL devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: QDEL devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de QDEL ( 1.4% par an) devrait croître plus lentement que le marché de US ( 8.9% par an).

Croissance élevée des revenus: Le chiffre d'affaires de QDEL ( 1.4% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de QDEL devrait être faible dans 3 ans ( 6.2 %).

QuidelOrtho Croissance future

Future contrôle des critères 0/6

Informations clés

Mises à jour récentes de la croissance future

Consensus EPS estimates fall by 42%

Price target increased by 7.3% to US$53.00

QuidelOrtho Corporation Suspends Earnings Guidance for the Year 2024

Consensus EPS estimates fall by 89%

Price target decreased by 7.0% to US$56.40

Consensus EPS estimates fall by 602%

Recent updates

Lacklustre Performance Is Driving QuidelOrtho Corporation's (NASDAQ:QDEL) Low P/S

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Quidelortho Corporation Announces Executive Changes

QuidelOrtho Corporation to Report Q3, 2024 Results on Nov 07, 2024

Consensus EPS estimates fall by 42%

QuidelOrtho Corporation Appoints Jonathan Siegrist, PhD, as New Executive Vice President of Research and Development and Chief Technology Officer

Price target increased by 7.3% to US$53.00

QuidelOrtho (NASDAQ:QDEL) Seems To Be Using A Lot Of Debt

QuidelOrtho Corporation Appoints Lee Bowman as Chief Human Resources Officer

QuidelOrtho Corporation (NASDAQ:QDEL) Stock Catapults 38% Though Its Price And Business Still Lag The Industry

QuidelOrtho Corporation(NasdaqGS:QDEL) dropped from S&P 400

QuidelOrtho Corporation to Report Q2, 2024 Results on Jul 31, 2024

QuidelOrtho Corporation Suspends Earnings Guidance for the Year 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

QuidelOrtho Corporation Announces CEO Changes

New major risk - Revenue and earnings growth

QuidelOrtho Corporation to Report Q1, 2024 Results on May 08, 2024

Labaton Keller Sucharow LLP Announces Securities Class Action Lawsuit Filed Against QuidelOrtho Corporation and Certain Executives

QuidelOrtho: Attractive Valuation Despite Weak Performance

Labaton Keller Sucharow LLP Announces Securities Class Action Lawsuit Filed Against QuidelOrtho Corporation and Certain Executives

We Think QuidelOrtho (NASDAQ:QDEL) Is Taking Some Risk With Its Debt

Consensus EPS estimates fall by 89%

Price target decreased by 7.0% to US$56.40

QuidelOrtho Corporation Receives FDA 510(K) Clearance for its QuickVue COVID-19 Test

Consensus EPS estimates fall by 602%

QuidelOrtho Corporation Announces CEO Changes

Consensus EPS estimates have been downgraded.

QuidelOrtho Corporation's (NASDAQ:QDEL) 38% Dip In Price Shows Sentiment Is Matching Revenues

New minor risk - Share price stability

Full year 2023 earnings: EPS and revenues miss analyst expectations

QuidelOrtho Corporation Provides Earnings Guidance for the Fiscal Year 2024

President exercised options and sold US$509k worth of stock

QuidelOrtho Corporation to Report Q4, 2023 Results on Feb 13, 2024

QuidelOrtho Corporation Provides Revenue Guidance for the Year 2023

QuidelOrtho Corporation Receives 510(K) Clearance for Savanna(R) Multiplex Molecular Platform and Savanna(R) HSV 1+2/VZV PCR Assay

Price target decreased by 7.8% to US$101

QuidelOrtho Corporation Announces Board Changes

Price target decreased by 9.5% to US$110

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

QuidelOrtho Corporation Provides Earnings Guidance for the Year 2023

QuidelOrtho Corporation to Report Q3, 2023 Results on Nov 01, 2023

QuidelOrtho Corporation Receives CLIA Waiver for Sofia 2 SARS Antigen+ FIA

QuidelOrtho Corporation Announces Resignation of Christopher M. Smith from the Board, Effective August 31, 2023

Consensus EPS estimates fall by 31%

QuidelOrtho Corporation Revises Earnings Guidance for the Year 2023

New major risk - Financial position

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

QuidelOrtho Corporation to Report Q2, 2023 Results on Aug 08, 2023

Consensus EPS estimates fall by 12%, revenue upgraded

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

QuidelOrtho Corporation Revises Earnings Guidance for the Year 2023

QuidelOrtho Corporation (NASDAQ:QDEL) Shares Could Be 38% Below Their Intrinsic Value Estimate

Independent Non-Executive Chairman exercised options and sold US$538k worth of stock

QuidelOrtho Corporation Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

President exercised options and sold US$393k worth of stock

QuidelOrtho Corporation Provides Financial Guidance for the Fiscal Year 2023

President exercised options and sold US$341k worth of stock

Consensus forecasts updated

QuidelOrtho Corporation Provides Revenue Guidance for the Fourth Quarter and Full Year Ended January 1, 2023

QuidelOrtho Corporation Announces Health Canada Grants License for Quidel TriageTrue High-Sensitivity Troponin I Test to Aid in the Diagnosis of Myocardial Infarction

Investor sentiment deteriorated over the past week

QuidelOrtho Corporation Announces Executive Changes

An Intrinsic Calculation For QuidelOrtho Corporation (NASDAQ:QDEL) Suggests It's 47% Undervalued

General Counsel exercised options and sold US$173k worth of stock

High number of new directors

General Counsel exercised options and sold US$173k worth of stock

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

President & COO exercised options and sold US$16k worth of stock

Investor sentiment improved over the past week